Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer—study protocol of the OPTIMA study
Abstract Background Patients with advanced colorectal cancer (CRC) commonly receive irinotecan-based systemic treatment to alleviate symptoms, improve quality of life (QoL), and prolong overall survival (OS). However, predicting efficacy and toxicity of the treatment is challenging. Previous researc...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14500-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399829015298048 |
|---|---|
| author | E. Russ J. Ziemons L. E. Hillege S. M. J. van Kuijk E. M. de Jong C. Elbers M. J. Deenen L. H. Borghuis T. M. M. Böhm P. Kristen L. C. Valk I. E. G. van Hellemond H. Vestjens A. Dietvorst A. Baars A. N. M. Goosens L. Vermeulen T. E. Buffart J. de Vos-Geelen J. Penders M. R. Redinbo L. Valkenburg-van Iersel M. L. Smidt |
| author_facet | E. Russ J. Ziemons L. E. Hillege S. M. J. van Kuijk E. M. de Jong C. Elbers M. J. Deenen L. H. Borghuis T. M. M. Böhm P. Kristen L. C. Valk I. E. G. van Hellemond H. Vestjens A. Dietvorst A. Baars A. N. M. Goosens L. Vermeulen T. E. Buffart J. de Vos-Geelen J. Penders M. R. Redinbo L. Valkenburg-van Iersel M. L. Smidt |
| author_sort | E. Russ |
| collection | DOAJ |
| description | Abstract Background Patients with advanced colorectal cancer (CRC) commonly receive irinotecan-based systemic treatment to alleviate symptoms, improve quality of life (QoL), and prolong overall survival (OS). However, predicting efficacy and toxicity of the treatment is challenging. Previous research indicated an association between the tumor molecular profile and response to irinotecan-based systemic treatment. Moreover, the UGT1A1 genotype of the patient, and the activity of the gut microbial enzyme β-glucuronidase (GUS) have been suggested as biomarkers for the development of systemic (e.g. neutropenia) and gastrointestinal toxicity (e.g. diarrhea) respectively. Therefore, the OPTIMA study will evaluate in patients with advanced CRC: 1) whether tumor molecular profiling can predict the efficacy of irinotecan-based systemic treatment; 2) whether high bacterial GUS enzyme activity is associated with increased gastrointestinal toxicity, decreased QoL and OS; as well as 3) the safety of a 70% irinotecan dose intensity in UGT1A1 poor metabolizers (PMs). Methods This prospective, observational, multi-center cohort study will include patients with advanced CRC scheduled for irinotecan-based systemic treatment. Archived tumor tissue and routine CT/MRI scans at baseline and after four cycles will be used to investigate the association of tumor molecular profile and treatment response according to RECIST. Before treatment initiation, germline DNA obtained from whole blood will be genotyped using PCR to determine the UGT1A1*28 genotype, followed by 30% irinotecan dose reduction in UGT1A1 PMs. Bacterial GUS activity will be quantified in fecal samples collected before and during treatment by means of an enzyme activity assay and will be related to patient-reported gastrointestinal toxicity (mainly diarrhea). Additionally, patients will fill in questionnaires concerning QoL, medication use, medical history and comorbidities, dietary habits, as well as physical performance. OS will be documented, capturing the duration from the start of treatment until death from any cause. Discussion Results obtained in the context of the OPTIMA study are expected to contribute to the optimization of efficacy and the reduction of toxicity of irinotecan-based systemic treatment, thereby potentially improving QoL of patients. Given that maintaining QoL is particularly critical in the palliative setting, the OPTIMA study has the potential to be of significant benefit for patients and their caregivers. Trial registration This trial is registered in the ClinicalTrials.gov register (NCT05655780) on December 16th, 2022. |
| format | Article |
| id | doaj-art-869e0b9e66e84e9a834cd5d1f24bb5aa |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-869e0b9e66e84e9a834cd5d1f24bb5aa2025-08-20T03:38:14ZengBMCBMC Cancer1471-24072025-07-012511810.1186/s12885-025-14500-6Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer—study protocol of the OPTIMA studyE. Russ0J. Ziemons1L. E. Hillege2S. M. J. van Kuijk3E. M. de Jong4C. Elbers5M. J. Deenen6L. H. Borghuis7T. M. M. Böhm8P. Kristen9L. C. Valk10I. E. G. van Hellemond11H. Vestjens12A. Dietvorst13A. Baars14A. N. M. Goosens15L. Vermeulen16T. E. Buffart17J. de Vos-Geelen18J. Penders19M. R. Redinbo20L. Valkenburg-van Iersel21M. L. Smidt22GROW– Research Institute for Oncology and Reproduction, Maastricht UniversityGROW– Research Institute for Oncology and Reproduction, Maastricht UniversityGROW– Research Institute for Oncology and Reproduction, Maastricht UniversityDepartment of Epidemiology, Faculty of Health, Medicine and Life Sciences, Maastricht UniversityDepartment of Surgery, Maastricht University Medical Center+Amsterdam UMC Location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and RadiobiologyDepartment of Clinical Pharmacy, Catharina HospitalAmsterdam UMC Location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and RadiobiologyDepartment of Clinical Pharmacy, Catharina HospitalGROW– Research Institute for Oncology and Reproduction, Maastricht UniversityWageningen University & ResearchDepartment of Internal Medicine, Catharina HospitalDepartment of Internal Medicine, VieCuriDepartment of Internal Medicine, Van Weel-Bethesda HospitalDepartment of Internal Medicine, Hospital Gelderse ValleiDepartmnet of Internal Medicine, Rode Kruis HospitalAmsterdam UMC Location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and RadiobiologyCancer Center AmsterdamGROW– Research Institute for Oncology and Reproduction, Maastricht UniversityNUTRIM– Research Institute of Nutrition and Translational Research In Metabolism, Maastricht UniversityDepartments of Chemistry, Biochemistry & Biophysics, and Microbiology & Immunology, University of North CarolinaGROW– Research Institute for Oncology and Reproduction, Maastricht UniversityGROW– Research Institute for Oncology and Reproduction, Maastricht UniversityAbstract Background Patients with advanced colorectal cancer (CRC) commonly receive irinotecan-based systemic treatment to alleviate symptoms, improve quality of life (QoL), and prolong overall survival (OS). However, predicting efficacy and toxicity of the treatment is challenging. Previous research indicated an association between the tumor molecular profile and response to irinotecan-based systemic treatment. Moreover, the UGT1A1 genotype of the patient, and the activity of the gut microbial enzyme β-glucuronidase (GUS) have been suggested as biomarkers for the development of systemic (e.g. neutropenia) and gastrointestinal toxicity (e.g. diarrhea) respectively. Therefore, the OPTIMA study will evaluate in patients with advanced CRC: 1) whether tumor molecular profiling can predict the efficacy of irinotecan-based systemic treatment; 2) whether high bacterial GUS enzyme activity is associated with increased gastrointestinal toxicity, decreased QoL and OS; as well as 3) the safety of a 70% irinotecan dose intensity in UGT1A1 poor metabolizers (PMs). Methods This prospective, observational, multi-center cohort study will include patients with advanced CRC scheduled for irinotecan-based systemic treatment. Archived tumor tissue and routine CT/MRI scans at baseline and after four cycles will be used to investigate the association of tumor molecular profile and treatment response according to RECIST. Before treatment initiation, germline DNA obtained from whole blood will be genotyped using PCR to determine the UGT1A1*28 genotype, followed by 30% irinotecan dose reduction in UGT1A1 PMs. Bacterial GUS activity will be quantified in fecal samples collected before and during treatment by means of an enzyme activity assay and will be related to patient-reported gastrointestinal toxicity (mainly diarrhea). Additionally, patients will fill in questionnaires concerning QoL, medication use, medical history and comorbidities, dietary habits, as well as physical performance. OS will be documented, capturing the duration from the start of treatment until death from any cause. Discussion Results obtained in the context of the OPTIMA study are expected to contribute to the optimization of efficacy and the reduction of toxicity of irinotecan-based systemic treatment, thereby potentially improving QoL of patients. Given that maintaining QoL is particularly critical in the palliative setting, the OPTIMA study has the potential to be of significant benefit for patients and their caregivers. Trial registration This trial is registered in the ClinicalTrials.gov register (NCT05655780) on December 16th, 2022.https://doi.org/10.1186/s12885-025-14500-6Colorectal cancerIrinotecanChemotherapy efficacyToxicityConsensus molecular subtypesUGT1A1 |
| spellingShingle | E. Russ J. Ziemons L. E. Hillege S. M. J. van Kuijk E. M. de Jong C. Elbers M. J. Deenen L. H. Borghuis T. M. M. Böhm P. Kristen L. C. Valk I. E. G. van Hellemond H. Vestjens A. Dietvorst A. Baars A. N. M. Goosens L. Vermeulen T. E. Buffart J. de Vos-Geelen J. Penders M. R. Redinbo L. Valkenburg-van Iersel M. L. Smidt Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer—study protocol of the OPTIMA study BMC Cancer Colorectal cancer Irinotecan Chemotherapy efficacy Toxicity Consensus molecular subtypes UGT1A1 |
| title | Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer—study protocol of the OPTIMA study |
| title_full | Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer—study protocol of the OPTIMA study |
| title_fullStr | Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer—study protocol of the OPTIMA study |
| title_full_unstemmed | Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer—study protocol of the OPTIMA study |
| title_short | Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer—study protocol of the OPTIMA study |
| title_sort | evaluation of potential biomarkers during irinotecan based systemic treatment for colorectal cancer study protocol of the optima study |
| topic | Colorectal cancer Irinotecan Chemotherapy efficacy Toxicity Consensus molecular subtypes UGT1A1 |
| url | https://doi.org/10.1186/s12885-025-14500-6 |
| work_keys_str_mv | AT eruss evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT jziemons evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT lehillege evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT smjvankuijk evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT emdejong evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT celbers evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT mjdeenen evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT lhborghuis evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT tmmbohm evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT pkristen evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT lcvalk evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT iegvanhellemond evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT hvestjens evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT adietvorst evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT abaars evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT anmgoosens evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT lvermeulen evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT tebuffart evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT jdevosgeelen evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT jpenders evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT mrredinbo evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT lvalkenburgvaniersel evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy AT mlsmidt evaluationofpotentialbiomarkersduringirinotecanbasedsystemictreatmentforcolorectalcancerstudyprotocoloftheoptimastudy |